SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies (BMNR) is generating significant buzz following its shareholder meeting, where the approval of a substantial increase in authorized shares and a strategic investment in a prominent content creator's company have sparked intense debate. The community is sharply divided, with many expressing concerns over potential dilution and the strategic rationale of the new investment, while others view these moves as a visionary play to expand reach and diversify beyond its core Ethereum holdings. This divergence in opinion, alongside the stock's performance relative to Ethereum, continues to fuel active discussion.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood ($HOOD) is seeing intense conversation following news of indefinitely delayed U.S. crypto legislation, which its CEO suggests negatively impacts American customers and has led to a significant stock decline. This, along with notices of planned future insider share sales, fuels bearish speculation about the company's valuation and near-term price action among some traders. However, a strong bullish contingent points to robust revenue growth and the booming success of prediction markets as key drivers, framing the current dip as a compelling buying opportunity.

Springview Holdings Ltd. engages in the design and construction of residential and commercial buildings. It involves new construction, reconstruction, alterations, and other general contracting services. The company was founded in 2002 and is headquartered in Singapore.

Springview Holdings Ltd - Ordinary Shares - Class A

Springview Holdings Ltd

Springview Holdings Ltd (SPHL) is trending following an explosive price surge, driven by its ultra-low share float and strong short squeeze potential. The trading community is actively discussing substantial gains and comparing SPHL to other recent high-volatility micro-cap runners, alongside frustrations over some brokers restricting trading activity.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science (MLEC) is trending following its recent 1-for-15 reverse stock split, which created an ultra-low share float. This has ignited significant community discussion and speculation about a potential short squeeze, drawing comparisons to other high-volatility, low-float runners like $SPHL. Despite some frustration over frequent trading halts, investors are actively discussing its potential for substantial upward price movement.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile (ASTS) is soaring to new all-time highs, definitively closing above $100 for the first time, driven by reports of a recent satellite breakthrough. Long-term investors are celebrating this major milestone and anticipating further gains, contrasting sharply with persistent bearish sentiment challenging the pre-revenue valuation and potential need for more capital. Community dialogue highlights the critical need for ASTS's direct-to-cell satellite connectivity, underscored by recent telecom outages, and speculates on upcoming launches and government contract catalysts.

TryHard Holdings Ltd. is a lifestyle entertainment company that operates in Japan offering a diverse range of services across the entertainment and hospitality sectors. It operates through the following business segments: Consultancy and management, Event curation, Sub-leasing and Restaurants. The Consultancy and management segment provides expert services to clubs, including operations, event management, and strategic support to enhance performance and engagement. The Event curation segment organize and produce own events, also provides a full suite of services, including event planning, construction, entertainment booking, event operation, and ticket sales. The Sub-Leasing segment acts as an intermediary between landlords and clubs. The Restaurants segment operates several restaurants. The company was founded on October 16, 2013 and is headquartered in Osaka, Japan.

TryHard Holdings Ltd.

TryHard Holdings (THH) is actively trending as a recent IPO with significant volatility, fueled by announcements of a substantial equity purchase facility and a share repurchase program. The community is sharply divided, with many anticipating a major rebound or squeeze due to its low float, while others caution about it being a high-risk pump-and-dump, referencing patterns often seen with similar foreign-based offerings.

Regentis Biomaterials Ltd. engages in the development of tissue repair solutions. It focuses on orthopedic treatments through its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue such as inflamed cartilage and bone tissue. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

Regentis Biomaterials Ltd.

Regentis Biomaterials

Regentis Biomaterials is a trending topic following its recent IPO, with community discussion centered on its extremely low float of 1.25 million shares and a 180-day insider lock-up period, creating a strong short squeeze narrative. Many investors are anticipating significant price action, driven by recent patent news for its GelrinC product and expectations for further company updates.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

Structure Therapeutics (GPCR) is trending after releasing positive Phase 2b data for its oral GLP-1 receptor agonist, aleniglipron, demonstrating significant weight loss. The community is buzzing with speculation about a potential acquisition, especially given recent M&A activity in the competitive obesity drug sector. Investors are weighing the drug's efficacy and tolerability profile against rival therapies as a potential takeover target.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending due to recent significant capital raises, including a $750 million common stock offering and an upsizing of a convertible preferred equity placement to $3 billion led by Apollo. The community views these capital infusions as a clear signal for upcoming large-scale acquisitions, aligning with CEO Brad Jacobs' proven strategy of consolidating fragmented industries. Investors are highly optimistic about Brad Jacobs' M&A playbook and believe these moves will drive substantial long-term growth in the building products distribution sector.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending amid significant market volatility following its $7.75 billion all-cash acquisition of cybersecurity firm Armis and a notable analyst downgrade, intensifying concerns about AI's impact on the broader software sector. The stock has seen a sharp decline, leading to widespread community debate; many are frustrated by the persistent sell-off, while others view the current valuation as a compelling long-term buying opportunity for a high-quality company strategically positioned to integrate AI. Investors are actively discussing whether the market is overreacting to disruption fears, overlooking ServiceNow's core strengths and its potential to leverage AI for future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid

Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 patients.read more...

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials ChemDiv Extends CMC Services Collaboration for...

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. Dover...

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move that removes a key policy tailwind for vaccine developers, including Moderna, Novavax, CureVac, and Traws Pharma.The CDC reportedly deactivated its response last week and will now track bird flu alongside seasonal influenza, updating human monitoring data monthly, Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-07/bird-flu-emergency-response-ends-in-us-as-infections-decline">reported</a>.&nbsp;Animal transmission data will no longer be published, the agency said. Washington and California, two of the most affected states, have also scaled back efforts.&nbsp;California ended its emergency declaration in April, while Washington is downsizing its public health response. The U.S. Department of Health and Human Services stated that the CDC’s transition reflects a return to regular program operations.&nbsp;During the response, 375 CDC staff had been assigned to the outbreak, the agency added.The CDC’s move comes amid broader federal cutbacks. Earlier this year, HHS scrapped a $766 million deal with Moderna for developing mRNA bird flu vaccines.Public health officials said a decline in surveillance would make it harder to spot the next outbreak.&nbsp; “We are letting our guard down,” said Michael Kinch, an infectious disease expert at Stony Brook University.In January, heightened bird flu fears had boosted attention on pandemic-preparedness companies.&nbsp;The U.S. reported its first human death from H5N1 in Louisiana and awarded $306 million for avian flu response, including $176 million to&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> for its mRNA-1018 vaccine candidate.<a href="https://stocktwits.com/symbol/NVAX">Novavax</a> had been advancing pre-clinical H5N1 vaccine research, while Germany’s&nbsp;<a href="https://stocktwits.com/symbol/CVAC">CureVac</a> partnered with&nbsp;<a href="https://stocktwits.com/symbol/GSK">GlaxoSmithKline</a> on another bird flu shot.&nbsp;Traws Pharma, which is developing a one-dose antiviral therapy called tivoxavir marboxil, disclosed promising preclinical results in December 2024 and plans a Phase 2 trial this year.Bird flu has infected at least 70 people in the U.S. since the start of the outbreak, mostly agricultural workers. While most cases have been mild, one fatality was recorded in January. The virus remains a concern in migratory birds and cattle.Retail sentiment on Stocktwits was mixed across vaccine makers: ‘bullish’ for Moderna and GSK, ‘neutral’ for Novavax, and ‘bearish’ for CureVac. Meanwhile, message volume was ‘high’ for GSK, ‘normal’ for Moderna and Novavax, and ‘extremely low’ for CureVac.Year to date, Moderna shares are down 28.8%, Novavax has fallen 22.9%, while CureVac has gained 56.8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.

Equity

Traws Pharma shares surged more than 200% on Monday, reaching highs seen in June after the company announced significant progress in developing its investigational one-dose influenza therapy, tivoxavir marboxil, for H5N1 bird flu treatment.&nbsp;Trading volume skyrocketed to over 2,600 times the daily average.In laboratory studies, tivoxavir marboxil demonstrated efficacy against highly pathogenic H5N1 influenza isolates.&nbsp;Traws’ Chief Science Officer David Pauza highlighted preclinical results, showing complete survival and reduced lung virus levels in mice infected with human H5N1 isolated from a dairy worker exposed to infected cattle.&nbsp;CEO Werner Cautreels added that Phase 1 clinical trial data confirmed the therapy’s safety and tolerability.&nbsp;A Phase 2 study is planned for the first half of 2025, the company said.The announcement comes amid escalating concerns over H5N1’s&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.nbcnews.com/health/health-news/bird-flu-cases-spread-warning-signs-rcna185084">spread</a>.&nbsp;The U.S. has reported 64 infections since April, with dairy herds in 16 states affected.&nbsp;Last week, California declared a state of emergency after an uptick in cases among dairy cows, and Louisiana reported the country’s first severe human infection.Retail interest&nbsp;in Traws surged on Monday, making its stock one of the top three trending symbols on Stocktwits.&nbsp;Discussions on the platform were mixed, with some predicting a breakout above $20 — a level last seen in April — and others cautioning about a potential share offering due to the company’s tight financial position.&nbsp;<stembedurl>https://stocktwits.com/miraclehunter/message/597607177</stembedurl><stembedurl>https://stocktwits.com/MarketAce/message/597606552</stembedurl>As of the last quarter, Traws had $5.4 million in cash and $11 million in liabilities, according to data on Koyfin.In addition to tivoxavir marboxil, Traws Pharma’s pipeline includes ratutrelvir for COVID-19, targeting viral proteases, and investigational cancer therapies like narazaciclib and rigosertib, which focus on cell cycle proteins.Traws Pharma began trading on&nbsp;the Nasdaq in April following the acquisition of Trawsfynydd Therapeutics by Onconova Therapeutics.&nbsp;Still, the stock remains down 24% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A view of chickens and a rooster at a farm as California declares a state of emergency to prevent a new public health crisis on Bird flu in Pescadero, California, United States on December 20, 2024. (Photo by Tayfun Coskun/Anadolu via Getty Images)

Traws Pharma Stock Hits 6-Month Highs On Bird Flu Treatment Breakthrough, Retail Interest Soars

The U.S. has reported H5N1 Bird Flu 64 infections since April, with dairy herds in 16 states affected. 

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Traws Pharma Inc.

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.91	--	--	N/A
Q3 '25	--	-$0.34	--	N/A
Q2 '25	--	-$0.11	--	N/A
Q1 '25	--	$2.09	--	N/A
Q4 '24	-$9.55	$101.35	1161.26%	BEAT

TRAW
Traws Pharma Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest TRAW News

TRAWTraws Pharma Inc.